Danaher To Acquire Abcam In About $5.7 Bln All-cash Deal
(RTTNews) - Science and technology innovator Danaher Corp. (DHR) announced Monday that it has entered into a definitive agreement to acquire Cambridge, UK-based Abcam plc (ABCM), a supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion, including assumed indebtedness and net of acquired cash.
Abcam is expected to operate as a standalone operating company and brand within Danaher's Life Sciences segment, furthering Danaher's strategy to help map complex diseases and accelerate the drug discovery process.
Danaher expects to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper.
The transaction is anticipated to close mid-2024 and is subject to customary conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval.
Danaher, Cincinnati Children's Hospital Partner To Improve Patient Safety In Early Clinical Trials
Abcam To Initiate Process To Explore Strategic Alternatives, Including Potential Sale
Danaher Guides Q1, FY23 Revenue Growth Above Estimates - Update
TSX Ends Weak As Communications, Tech Stocks Decline
Dollar Rises Against Major Counterparts
Swiss Market Ends On Weak Note After Choppy Session
U.S. Dollar Jumps After Jobs Data
